SLC12A5 and glioblastoma: In the study, we discuss below the differences in the expression of SLC12A2, SLC12A5, CDH1, CDH2, EZH2, and GFAP in primary GBM IDH-wild-type female cells (GBM5-1F, GBM5-2F, and GBM5-3F), and the differences in the response of the tested cells to the effects of the treatment with NaVPA–NaDCA compared to the impact of the treatment with TMZ.